Clarke, BA;
Witkowski, L;
Ton Nu, TN;
Shaw, PA;
Gilks, CB;
Huntsman, D;
Karnezis, AN;
... McCluggage, WG; + view all
(2016)
Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
Histopathology
, 69
(5)
pp. 727-738.
10.1111/his.12988.
Preview |
Text
Clarke_Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry AAM.pdf Download (193kB) | Preview |
Abstract
AIMS: Molecular investigation of small-cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) has revealed that it is a monogenetic tumour characterized by alteration of SMARCA4 (BRG1), encoding a member of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodelling complex. A large majority of cases show loss of expression of the corresponding SMARCA4/BRG1 protein. Furthermore, three cases of SCCOHT with retained SMARCA4 protein expression showed loss of SMARCB1/INI1 expression. The aim of this study was to assess the sensitivity and specificity of loss of SMARCA4 expression as a diagnostic test for SCCOHT. METHODS AND RESULTS: We performed SMARCA4 and SMARCB1 staining in 245 tumours, many of which were potentially in the differential diagnosis of SCCOHT. We also stained 56 cases of SCCOHT for SMARCA4 and 37 of these for SMARCB1. Fifty-four of the SCCOHT cases showed complete absence of SMARCA4 expression. The two cases with retained expression showed molecular alteration of SMARCA4. Of the 217 other neoplasms with interpretable staining, all retained SMARCA4 expression. Although the majority showed diffuse, strong nuclear expression, a heterogeneous, typically weak staining pattern was present in 13% of cases. All 37 cases of SCCOHT tested and all other neoplasms, apart from three malignant rhabdoid tumours, showed retained nuclear SMARCB1 expression. Loss of SMARCA4 expression had a sensitivity of 96.55% and specificity of 100%. CONCLUSIONS: Loss of SMARCA4 expression is sensitive and specific for SCCOHT. Although some mimics show heterogeneous expression, there is retention of nuclear staining in at least a part of the tumour; therefore, only complete loss of staining should be regarded as being supportive of SCCOHT.
Type: | Article |
---|---|
Title: | Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1111/his.12988 |
Publisher version: | http://dx.doi.org/10.1111/his.12988 |
Language: | English |
Additional information: | Copyright © 2016 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: [Clarke, BA; Witkowski, L; Ton Nu, TN; Shaw, PA; Gilks, CB; Huntsman, D; Karnezis, AN; (2016) Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology , 69 (5) pp. 727-738. 10.1111/his.12988], which has been published in final form at http://dx.doi.org/10.1111/his.12988. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |
Keywords: | SMARCA4, SMARCB1, differential diagnosis, immunohistochemistry, ovary, small-cell carcinoma of ovary (hypercalcaemic type) |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Population, Policy and Practice Dept |
URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1490287 |
Archive Staff Only
View Item |